Evidence map›Paper›PMID 30939815›Full record

ArticleViruses2019

Development of a Versatile, Near Full Genome Amplification and Sequencing Approach for a Broad Variety of HIV-1 Group M Variants.

Andrew N Banin, Michael Tuen, Jude S Bimela, Marcel Tongo, Paul Zappile, Alireza Khodadadi-Jamayran, Aubin J Nanfack, Josephine Meli, Xiaohong Wang, Dora Mbanya and 5 more

Abstract read
In one paragraph

Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Andrew N BaninDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. andybanin@gmail.com.
Michael TuenDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. Michael.Tuen@nyumc.org.
Jude S BimelaDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. bimelajude@gmail.com.
Marcel TongoCenter of Research for Emerging and Re-Emerging Diseases (CREMER), Institute of Medical Research and Study of Medicinal Plants, BP 906 Yaoundé, Cameroon. marcel.tongo@gmail.com.
Paul ZappileDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. Paul.Zappile@nyumc.org.
Alireza Khodadadi-JamayranApplied Bioinformatics Laboratories (ABL) and Genome Technology Center (GTC), Division of Advanced Research Technologies (DART), New York University Langone Medical Center, New York, NY 10016, USA. Adriana.Heguy@nyumc.org.
Aubin J NanfackDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. a_nanfack@yahoo.fr.
Josephine MeliMedical Diagnostic Center, BP 15810 Yaoundé, Cameroon. jmeli_cm@yahoo.fr.
Xiaohong WangManhattan Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA. Xiaohong.Wang@va.gov.
Dora MbanyaFaculty of Medicine and Biomedical Sciences, Department of Microbiology, Parasitology and Infectious Diseases, University of Yaoundé 1, BP 1364 Yaoundé, Cameroon. dmbanya1@yahoo.co.uk.
Jeanne NgogangFaculty of Medicine and Biomedical Sciences, Department of Biochemistry, University of Yaoundé 1, BP 1364 Yaoundé, Cameroon. alireza.khodadadi-jamayran@nyumc.org.
Adriana HeguyDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. Adriana.Heguy@nyumc.org.
Phillipe N NyambiDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. camacf01@nyumc.org.
Charles FokunangFaculty of Medicine and Biomedical Sciences, Department of Pharmacotoxicology & Pharmacokinetics, University of Yaoundé 1, BP 1364 Yaoundé, Cameroon. charlesfokunang@yahoo.co.uk.
Ralf DuerrDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA. Ralf.Duerr@nyumc.org.

Funding

Training Program on HIV Diversity and Drug Resistance-Enhancing Research CapacityD43TW009604 · FIC · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GORNY, MIROSLAW K · 2013 to 2017
$1.4M
FIC NIH HHS D43 TW009604Wellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

Near full genome sequencing (NFGS) of HIV-1 is required to assess the genetic composition of HIV-1 strains comprehensively. Population-wide, it enables a determination of the heterogeneity of HIV-1 and the emergence of novel/recombinant strains, while for each individual it constitutes a diagnostic instrument to assist targeted therapeutic measures against viral components. There is still a lack of robust and adaptable techniques for efficient NFGS from miscellaneous HIV-1 subtypes. Using rational primer design, a broad primer set was developed for the amplification and sequencing of diverse HIV-1 group M variants from plasma. Using pure subtypes as well as diverse, unique recombinant forms (URF), variable amplicon approaches were developed for NFGS comprising all functional genes. Twenty-three different genomes composed of subtypes A (A1), B, F (F2), G, CRF01_AE, CRF02_AG, and CRF22_01A1 were successfully determined. The NFGS approach was robust irrespective of viral loads (≥306 copies/mL) and amplification method. Third-generation sequencing (TGS), single genome amplification (SGA), cloning, and bulk sequencing yielded similar outcomes concerning subtype composition and recombinant breakpoint patterns. The introduction of a simple and versatile near full genome amplification, sequencing, and cloning method enables broad application in phylogenetic studies of diverse HIV-1 subtypes and can contribute to personalized HIV therapy and diagnosis.

Indexed as

Cloning, MolecularDNA PrimersGenotypeHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHumansNucleic Acid Amplification TechniquesPlasmaWhole Genome SequencingDNA Primersbulk sequencing and cloningHIV-1 group M subtype-independent approachNear full genome amplification and sequencingrational primer designsingle-genome amplification (SGA)third-generation sequencing (TGS)

Identifiers

PMID30939815
PMCPMC6520859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.